Helen Thackray
Chief Tech/Sci/R&D Officer at BIOCRYST PHARMACEUTICALS, INC.
Net worth: 2 M $ as of 29/06/2024
Helen Thackray active positions
| Companies | Position | Start | End |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 18/03/2021 | - |
| Director/Board Member | 19/09/2019 | 18/03/2021 | |
| Independent Dir/Board Member | 19/09/2019 | 18/03/2021 | |
| Holy Cross Hospital (Maryland) | Corporate Officer/Principal | - | - |
| Gw School of Medicine & Health Sciences | Corporate Officer/Principal | 31/12/1999 | - |
Career history of Helen Thackray
Former positions of Helen Thackray
| Companies | Position | Start | End |
|---|---|---|---|
| IMMUNOGEN, INC. | Director/Board Member | 21/09/2021 | 11/02/2024 |
| Independent Dir/Board Member | 21/09/2021 | 11/02/2024 | |
| GLYCOMIMETICS, INC. | Chief Tech/Sci/R&D Officer | 05/01/2012 | 18/03/2021 |
| Corporate Officer/Principal | 31/12/2005 | 05/01/2012 | |
Biosynexus, Inc.
 Biosynexus, Inc. Pharmaceuticals: MajorHealth Technology Biosynexus, Inc. develops and markets pharmaceutical products. The company is headquartered in Rockville, MD. | Corporate Officer/Principal | 31/12/2000 | 31/12/2005 |
| National Center for Health Statistics | Corporate Officer/Principal | - | - |
Training of Helen Thackray
| Stanford University | Undergraduate Degree |
| Gw School of Medicine & Health Sciences | Doctorate Degree |
Statistics
International
| United States | 9 |
Operational
| Corporate Officer/Principal | 5 |
| Chief Tech/Sci/R&D Officer | 2 |
| Director/Board Member | 2 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Government | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| BIOCRYST PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Biosynexus, Inc.
Biosynexus, Inc. Pharmaceuticals: MajorHealth Technology Biosynexus, Inc. develops and markets pharmaceutical products. The company is headquartered in Rockville, MD. | Health Technology |
| Holy Cross Hospital (Maryland) | |
| National Center for Health Statistics | Government |
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
- Stock Market
- Insiders
- Helen Thackray
- Experience
